JKSMRM 14:95-102(2010) Department of Radiology, College of Medicine, The Catholic University of Korea Clinical Research Coordinating Center, College of Medicine, The Catholic Medical Center Department of Surgery, College of Medicine, The Catholic University of Korea Received; September 27, 2010, revised; November 17, 2010, accepted; December 1, 2010 Corresponding author : Sung Hun Kim, M.D., De...

BACKGROUND Mammographic density is a potentially modifiable risk factor for breast cancer. To what extent mammographic density is a predictor for both hormone receptor-positive and hormone receptor-negative tumors is unclear. Even less is known about whether mammographic density predicts subtypes of breast cancer defined by expression status of the three receptors: estrogen receptor (ER), proge...

Genistein (Gen) has been reported as a protective factor against breast cancer. However, the molecular mechanism by which Gen elicits its effects on triple-negative breast cancer cells has not been fully elucidated. In our study, the breast cancer cell line MDA-MB-231 was selected to determine the action of Gen on triple-negative breast cancer cells. MTT assay, flow cytometric analysis, siRNA t...

BACKGROUND Recently, we reported an association of a novel cancer testis (CT) antigen, sperm-associated antigen 9 (SPAG9) expression in breast cancer clinical samples, indicating its potential role in carcinogenesis. Around 15% breast cancers are designated as triple-negative for which treatment modalities are limited. Therefore, in the present study, we assessed the role of SPAG9 in triple-neg...

Биологические маркеры тройного негативного рака молочной железы: поиск мишеней для иммунотаргетной и клеточной терапииBiomarkers and potential targets for immune cellular therapy in triple negative breast cancer

Triple negative breast cancers exhibit very aggressive features and poor patient outcomes. These tumors are enriched in cancer stem cells and exhibit resistance to most treatments and chemotherapy. In this study, we found the cyclin-dependent kinase (CDK4) to act as a cancer stem cell regulator and novel prognostic marker in triple negative breast cancers. We found CDK4 to be highly expressed i...

expression of estrogen, progesterone, and human epidermal growth factor 2 receptors, is a clinical subtype of breast cancer commonly associated with poor prognosis. It tends to be aggressively metastatic with a high recurrence rate and little response to standard chemotherapy [1]. Mounting evidence suggests that one triggering event in oncogenic transformation is an imbalance in acid-base homeo...

Introduction: Triple-negative breast cancer (TNBC) is a type of breast cancer that is negative for estrogen receptor, progesterone receptor, and HER2. This study aimed to evaluate the clinical outcomes and short-term prognosis of this type of cancer compared with other subtypes of breast cancer. Methods: A cross-sectional study was conducted on 108 women with invasive breast cancer. The patie...

Breast cancers with a basal-like gene signature are primarily triple-negative, frequently metastatic, and carry a poor prognosis. Basal-like breast cancers are enriched for markers of breast cancer stem cells as well as markers of epithelial-mesenchymal transition (EMT). While EMT is generally thought to be important in the process of metastasis, in vivo evidence of EMT in human disease remains...

The lack of effective treatment targets for triple-negative breast cancers make them unfitted for endocrine or HER2 targeted therapy, and their prognosis is poor. Transcription factor ER81, a downstream gene of the HER2, is highly expressed in breast cancer lines, breast atypical hyperplasia and primary breast cancers including triple-negative examples. However, whether and how ER81 affects bre...